Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Seibyl

Showing results (61-70 of 106) with videos related to

Pageof 11
Sort By:
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 3, 2017
Use of white matter reference regions for detection of change in florbetapir positron emission tomography from completed phase 3 solanezumab trialsAdam S Fleisher, Abhinay D Joshi, Karen L Sundell, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|March 3, 2018
CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohortsOskar Hansson, John Seibyl, Erik Stomrud, et al.
Synapse (New York, N.Y.)|October 9, 2012
Kinetic modeling and occupancy measures of the norepinephrine transporters in baboons using single photon emission computed tomography with (123)I-INERAdriana Alexandre dos Santos Tavares, Olivier Barret, Jeffery Batis, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 14, 2011
SNM practice guideline for dopamine transporter imaging with 123I-ioflupane SPECT 1.0David S W Djang, Marcel J R Janssen, Nicolaas Bohnen, et al.
Annals of Neurology|January 20, 2026
Toward Harmonizing Quantification of Dopamine Neuron Imaging Biomarkers in Parkinson's Disease: The Centamine ScaleZhen Fan, Graham Searle, Gaia Rizzo, et al.
Clinical and Translational Science|February 2, 2019
Molecular Neuroimaging of the Dopamine Transporter as a Patient Enrichment Biomarker for Clinical Trials for Early Parkinson's DiseaseKlaus Romero, Daniela Conrado, Jackson Burton, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 13, 2021
Dopamine D<sub>1</sub> Receptor Agonist PET Tracer Development: Assessment in Nonhuman PrimatesOlivier Barret, Lei Zhang, David Alagille, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|June 28, 2014
Aβ imaging with 18F-florbetaben in prodromal Alzheimer's disease: a prospective outcome studyKevin T Ong, Victor L Villemagne, Alex Bahar-Fuchs, et al.
Archives of Neurology|April 17, 2008
Serum urate as a predictor of clinical and radiographic progression in Parkinson diseaseMichael A Schwarzschild, Steven R Schwid, Kenneth Marek, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 12, 2014
A practical approach to remote longitudinal follow-up of Parkinson's disease: the FOUND studyCaroline M Tanner, Cheryl C Meng, Bernard Ravina, et al.
Pageof 11

Showing results (61-70 of 106) with videos related to

Sort By:
Pageof 11
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|April 3, 2017
Use of white matter reference regions for detection of change in florbetapir positron emission tomography from completed phase 3 solanezumab trialsAdam S Fleisher, Abhinay D Joshi, Karen L Sundell, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|March 3, 2018
CSF biomarkers of Alzheimer's disease concord with amyloid-β PET and predict clinical progression: A study of fully automated immunoassays in BioFINDER and ADNI cohortsOskar Hansson, John Seibyl, Erik Stomrud, et al.
Synapse (New York, N.Y.)|October 9, 2012
Kinetic modeling and occupancy measures of the norepinephrine transporters in baboons using single photon emission computed tomography with (123)I-INERAdriana Alexandre dos Santos Tavares, Olivier Barret, Jeffery Batis, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|December 14, 2011
SNM practice guideline for dopamine transporter imaging with 123I-ioflupane SPECT 1.0David S W Djang, Marcel J R Janssen, Nicolaas Bohnen, et al.
Annals of Neurology|January 20, 2026
Toward Harmonizing Quantification of Dopamine Neuron Imaging Biomarkers in Parkinson's Disease: The Centamine ScaleZhen Fan, Graham Searle, Gaia Rizzo, et al.
Clinical and Translational Science|February 2, 2019
Molecular Neuroimaging of the Dopamine Transporter as a Patient Enrichment Biomarker for Clinical Trials for Early Parkinson's DiseaseKlaus Romero, Daniela Conrado, Jackson Burton, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|February 13, 2021
Dopamine D<sub>1</sub> Receptor Agonist PET Tracer Development: Assessment in Nonhuman PrimatesOlivier Barret, Lei Zhang, David Alagille, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|June 28, 2014
Aβ imaging with 18F-florbetaben in prodromal Alzheimer's disease: a prospective outcome studyKevin T Ong, Victor L Villemagne, Alex Bahar-Fuchs, et al.
Archives of Neurology|April 17, 2008
Serum urate as a predictor of clinical and radiographic progression in Parkinson diseaseMichael A Schwarzschild, Steven R Schwid, Kenneth Marek, et al.
Movement Disorders : Official Journal of the Movement Disorder Society|February 12, 2014
A practical approach to remote longitudinal follow-up of Parkinson's disease: the FOUND studyCaroline M Tanner, Cheryl C Meng, Bernard Ravina, et al.
Pageof 11